(Q36986520)

17 August 2017

1 reference

title

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? (English)

1 reference

17 August 2017

O'Hagan DT

1

1 reference

17 August 2017

Wack A

series ordinal

2

1 reference

17 August 2017

Podda A

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

31 October 2007

1 reference

Clinical Pharmacology & Therapeutics

17 August 2017

1 reference

17 August 2017

82

1 reference

17 August 2017

6

1 reference

17 August 2017

740-744

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100402

17 August 2017

0 references

cites work

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

Adjuvant activity of incomplete Freund's adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

The safety of vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Dendritic cells internalize vaccine adjuvant after intramuscular injection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

A universal vaccine for serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100402

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100402

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference